Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Placebo Controlled, Double-blind, 4 Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Ulcerative Colitis.

Trial Profile

A Phase II Randomized, Placebo Controlled, Double-blind, 4 Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Ulcerative Colitis.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs SHR 0302 (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Reistone Biopharma
  • Most Recent Events

    • 22 Oct 2018 According to a Reistone Biopharma media release, the US FDA has approved the IND for phase II clinical trial to investigate the efficacy and safety of SHR-0302 in moderate to severe ulcerative colitis (UC).
    • 25 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top